As a PhD student at the division of Pharmacoepidemiology and Clinical Pharmacology at Utrecht University, I am very interested in the complexities and methodologies in the context of decision-making for (innovative) medicines. My research primarily focuses on the implementation of the recently adopted European Regulation on Health Technology Assessment (EU HTAR). This regulation aims to harmonize the clinical aspects of HTA procedures for medicines throughout the European Union. Concurrently, I hold a role as a pharmacotherapeutic assessor at the National Health Care Institute, where I evaluate the relative clinical effectiveness of new medicines to inform decision-making on their reimbursement.